Savara Inc Additional Paid in Capital, Common Stock
Savara Inc (SVRA) had Additional Paid in Capital, Common Stock of $829.59 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital, Common Stock $829.59M.
- 2026-03-31: Additional Paid in Capital, Common Stock $821.63M.
- 2025-12-31: Additional Paid in Capital, Common Stock $811.10M.
- 2025-09-30: Additional Paid in Capital, Common Stock $670.22M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $829.59M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $821.63M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $811.10M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $670.22M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $666.82M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $664.20M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $661.28M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $659.08M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $538.43M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $536.18M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $533.87M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $524.62M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $448.89M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $447.83M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $446.94M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $446.38M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $445.93M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $445.47M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $444.90M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $444.04M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $443.34M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $442.25M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $320.89M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $320.08M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $316.33M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $310.70M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $309.56M 10-K · filed 2021-03-10 | |
| 2019-09-30 | $283.17M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $276.32M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $243.60M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $237.70M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $236.66M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $188.87M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $187.45M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $186.52M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $135.57M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $134.22M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $321.04M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $3.12M 10-K · filed 2018-03-14 | $320.58M 10-K · filed 2017-03-06 |
| 2016-09-30 | $317.99M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $313.10M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $306.66M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $298.71M 10-K · filed 2017-03-06 | |
| 2015-09-30 | $298.18M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $297.26M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $294.70M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $293.65M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $272.96M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $270.07M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $265.50M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $254.16M 10-K · filed 2015-03-24 | $254.15M 10-K · filed 2014-03-26 |
| 2013-09-30 | $253.71M 10-Q · filed 2013-11-04 | |
| 2013-06-30 | $253.27M 10-Q · filed 2013-08-05 | |
| 2013-03-31 | $227.05M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $226.70M 10-K · filed 2014-03-26 | |
| 2012-09-30 | $227.20M 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $226.79M 10-Q · filed 2012-08-06 | |
| 2012-03-31 | $226.45M 10-Q · filed 2012-05-07 | |
| 2011-12-31 | $226.12M 10-K · filed 2013-03-19 | |
| 2011-09-30 | $210.17M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $209.84M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $182.80M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |